Anemia in liver transplant recipients undergoing antiviral treatment for recurrent hepatitis C

Sammy Saab, Mina K. Oh, Ayman B. Ibrahim, Francisco Durazo, Steven Han, Hasan Yersiz, Douglas G. Farmer, R. Mark Ghobrial, Leonard I. Goldstein, Myron J. Tong, Ronald W. Busuttil – 28 June 2007 – Adherence to antiviral therapy is essential to achieve sustained virological responses in patients treated for hepatitis C. An important limitation to use of appropriate doses of ribavirin is development of anemia. The aim of this study is to identify risk factors associated with anemia in liver transplant recipients undergoing treatment for recurrent hepatitis C virus (HCV).

Short‐term induction therapy with anti‐thymocyte globulin and delayed use of calcineurin inhibitors in orthotopic liver transplantation

Thomas Soliman, Hubert Hetz, Christoph Burghuber, Georg Györi, Gerd Silberhumer, Rudolf Steininger, Ferdinand Mühlbacher, Gabriela A. Berlakovich – 28 June 2007 – The appropriate time point for starting immunosuppressive treatment with calcineurin inhibitors after orthotopic liver transplantation (OLT) has been a subject of debate. The aim of the study was to analyze the effects of anti‐thymocyte globulin (ATG) induction therapy on rejection, renal function, infection, tumor rate, and survival.

Complications associated with percutaneous placement of venous return cannula for venovenous bypass in adult orthotopic liver transplantation

Tetsuro Sakai, Raymond M. Planinsic, Ibetsam A. Hilmi, J. Wallis Marsh – 28 June 2007 – Percutaneous large bore cannula placement during orthotopic liver transplantation (OLT) for use in venovenous bypass (VVB) has been reported to be a rapid and simple technique. It is, however, a technique that carries its own risks. The aim of the study was to investigate the incidence of complications related to the placement of a percutaneous venous return cannula and subsequent VVB in OLT.

Attitude of hospital personnel faced with living liver donation in a Spanish center with a living donor liver transplant program

A. Ríos, P. Ramírez, M.M. Rodríguez, L. Martínez, J.M. Rodríguez, P.J. Galindo, P. Parrilla – 28 June 2007 – In Spain, despite its high rate of cadaveric donation, death while on the liver transplant waiting list is high. For this reason, living liver donation is being encouraged despite of the risk of morbidity for the donor. The objective of this study was to analyze attitudes toward living liver donation among hospital personnel in a hospital with a recently authorized living donor liver transplantation program.

Impaired liver regeneration and increased oval cell numbers following T cell–mediated hepatitis

Ian N. Hines, Michael Kremer, Fuyumi Isayama, Ashley W. Perry, Richard J. Milton, April L. Black, Christy L. Byrd, Michael D. Wheeler – 27 June 2007 – The regeneration of liver tissue following transplantation is often complicated by inflammation and tissue damage induced by a number of factors, including ischemia and reperfusion injury and immune reactions to the donor tissue. The purpose of the current study is to characterize the effects of T cell–mediated hepatitis induced by concanavalin A (ConA) on the regenerative response in vivo.

Telangiectatic adenoma: An entity associated with increased body mass index and inflammation

Valérie Paradis, Axelle Champault, Maxime Ronot, Lydia Deschamps, Dominique‐Charles Valla, Dominique Vidaud, Valérie Vilgrain, Jacques Belghiti, Pierre Bedossa – 27 June 2007 – What were previously called telangiectatic focal nodular hyperplasias are in fact true adenomas with telangiectatic features (TAs) without overt characterized genetic abnormalities. The aim of our study was to review a surgical series of TAs in order to describe clinical, biological, and radiological findings of these lesions and to evaluate their outcomes.

Antiviral drug‐resistant HBV: Standardization of nomenclature and assays and recommendations for management

Anna S. Lok, Fabien Zoulim, Stephen Locarnini, Angeline Bartholomeusz, Marc G. Ghany, Jean‐Michel Pawlotsky, Yun‐Fan Liaw, Masashi Mizokami, Carla Kuiken – 27 June 2007 – Substantial advances have been made in the treatment of chronic hepatitis B in the past decade. Approved treatments for chronic hepatitis B include 2 formulations of interferon and 4 nucleos(t)ide analogues (NAs).

Subscribe to